Nonalcoholic fatty liver disease and cardiovascular risk

被引：19

作者：

Misra V.L. ^{[1
]}

Khashab M. ^{[1
]}

Chalasani N. ^{[1
]}

机构：

[1] Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Clarian/IU Digestive Diseases Center, Indianapolis, IN 46202

来源：

Current Gastroenterology Reports | 2009年 / 11卷 / 1期

关键词：

Metabolic Syndrome; Bariatric Surgery; NASH; Exenatide; Rimonabant;

D O I：

10.1007/s11894-009-0008-4

中图分类号：

学科分类号：

摘要：

Nonalcoholic fatty liver disease (NAFLD) is a very common cause of chronic liver disease in the United States. A large proportion of patients with NAFLD have coexisting metabolic syndrome, a major risk factor for cardiovascular disease. A strong association between NAFLD and cardiovascular disease has been long suspected, and recent studies have confirmed that cardiovascular disease is the single most important cause of mortality in this patient population. NAFLD may pose cardiovascular risk beyond the risk conferred by traditional factors such as dyslipidemia, diabetes, and smoking. Health care providers managing patients with NAFLD should recognize this increased cardiovascular risk and should undertake early, aggressive risk factor modification. © Springer Science+Business Media, LLC 2009.

引用

页码：50 / 55

页数：5

共 53 条

[31] Hector J., Schwarzloh B., Goehring J., Et al., TNF-alpha alters visfatin and adiponectin levels in human fat, Horm Metab Res, 39, pp. 250-255, (2007)
[32] Chandran M., Phillips S.A., Ciaraldi T., Henry R.R., Adiponectin: More than just another fat cell hormone?, Diabetes Care, 26, pp. 2442-2450, (2003)
[33] Huang M.A., Greenson J.K., Chao C.K., Et al., One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: A pilot study, Am J Gastroenterol, 100, pp. 1072-1081, (2005)
[34] Kechagias S., Ernersson A., Dahlqvist O., Et al., Fast-foodbased hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects, Gut, 57, pp. 649-654, (2008)
[35] Boyd S.T., Fremming B.A., Rimonabant - A selective CB1 antagonist, Ann Pharmacother, 39, pp. 684-690, (2005)
[36] Van Gaal L.F., Rissanen A.M., Scheen A.J., Et al., Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, Lancet, 365, pp. 1389-1397, (2005)
[37] Mallat A., Lotersztajn S., Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver, Am J Physiol Gastrointest Liver Physiol, 294, pp. 9-12, (2008)
[38] Buse J.B., Klonoff D.C., Nielsen L.L., Et al., Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials, Clin Ther, 29, pp. 139-153, (2007)
[39] Torgerson J.S., Hauptman J., Boldrin M.N., Sjostrom L., XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients, Diabetes Care, 27, pp. 155-161, (2004)
[40] Furuya Jr. C.K., de Oliveira C.P., de Mello E.S., Et al., Effects of bariatric surgery on nonalcoholic fatty liver disease: Preliminary findings after 2 years, J Gastroenterol Hepatol, 22, pp. 510-514, (2007)

← 1 2 3 4 5 6 →